Previsioni

Il prezzo obiettivo medio degli analisti è +4,55€ (+54,24%). La mediana è +4,55€ (+54,24%).

Acquista	4
Mantieni	6
Vendi	0

Notizie Vai al feed delle notizie

Recursion bets on AI and proprietary dataset to reshape drug discovery

At the Bank of America SMID Cap Virtual Conference, Recursion emphasized that AI can only create competitive advantages in drug discovery when combined with more than 50 petabytes of proprietary biological data and rigorous clinical execution. The company highlighted REC-4881 in familial adenomatous polyposis, which reduced polyp burden by 43% after 12 weeks and showed a 53% response rate after treatment pauses, and pointed to capital-efficient partnerships with Roche and Sanofi. Recursion has $556 million in cash (runway into early 2028) and cites upcoming catalysts such as additional clinical data, FDA discussions, and updates on RBM39 and PI3K. » Altro su de.investing.com
Cathie Wood's ARKG increases exposure to Recursion Pharmaceuticals

Ark Genomic Revolution ETF holds over $50 million of Recursion Pharmaceuticals as the company leverages AI, robotics and computer vision to generate large-scale biological data. Recursion has seven drug candidates in clinical stages, with REC-4881 showing proof-of-concept and additional phase 1b/2 data expected in the first half of 2027. The company has partnerships with Bayer, Roche and a technical collaboration with Nvidia, but currently has no approved drugs and limited revenue. Recursion forecasts funding into early 2028, making it a high-risk, speculative investment contingent on successful commercialization of its AI-driven pipeline. » Altro su finance.yahoo.com
Recursion Pharmaceuticals' annual general meeting approves all proposals

Shareholders of Recursion Pharmaceuticals elected Dr. Najat Khan and Dr. Franziska Michor to the supervisory board, approved a say-on-pay resolution for executive compensation, and confirmed PricewaterhouseCoopers as auditor for fiscal year 2026. The biotech company has a solid liquidity position but remains unprofitable with a trailing twelve-month EPS of -1.17. For Q1 2026, Recursion reported a better-than-expected EPS of -0.22 but missed revenue expectations significantly ($6.47 million vs. $16.28 million expected). » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Recursion Pharmaceuticals ha già distribuito 15,07€ di dividendi. L'ultimo pagamento è avvenuto a settembre 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Recursion Pharmaceuticals ha registrato ricavi pari a 6,72 Mio€ e un utile netto di −114,79 Mio€

(EUR)	giu 2026	YoY
Ricavi	+6,72 Mio	58,53%
Utile lordo	−3,35 Mio	272,98%
Utile netto	−114,79 Mio	21,29%
EBITDA	−98,60 Mio	21,25%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,57 Mrd€
Numero di azioni	524,68 Mio
Massimo/minimo a 52 settimane	+6,16€ - +2,38€
Dividendi	No
Beta	1,05
Rapporto P/E	−3,36
Rapporto PEG	−0,06
Rapporto P/B	+2,03
Rapporto P/S	+33,38

Profilo aziendale

Recursion Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich mit der Entschlüsselung der Biologie befasst, indem es technologische Innovationen aus den Bereichen Biologie, Chemie, Automatisierung, Datenwissenschaft und Technik integriert, um die Arzneimittelforschung zu industrialisieren. Das Unternehmen entwickelt REC-994, das sich in der klinischen Phase IIa zur Behandlung der zerebralen kavernösen Malformation befindet, REC-2282 zur Behandlung der Neurofibromatose Typ 2, REC-4881 zur Behandlung der familiären adenomatösen Polyposis und REC-3599, das sich in der klinischen Phase I zur Behandlung der GM2-Gangliosidose befindet. Zu den Produkten im präklinischen Stadium gehören REC-3964 zur Behandlung von Clostridium-difficile-Kolitis, REC-64917 zur Behandlung von neuralen oder systemischen Entzündungen, REC-65029 zur Behandlung von HRD-negativem Eierstockkrebs und REC-648918 zur Stärkung der Anti-Tumor-Immunität; REC-2029 zur Behandlung des Wnt-mutierten hepatozellulären Karzinoms; REC-14221 zur Behandlung von soliden und hämatologischen Malignomen; und REC-64151 zur Behandlung der Immun-Checkpoint-Resistenz bei KRAS/STK11-mutiertem nicht-kleinzelligem Lungenkrebs. Das Unternehmen unterhält Kooperationen und Vereinbarungen mit der Bayer AG, der University of Utah Research Foundation, der Ohio State Innovation Foundation, Chromaderm, Inc. und Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Salt Lake City, Utah.

Nome	Recursion Pharmaceuticals
CEO	Najat Khan
Sede centrale	Salt Lake City, ut Stati Uniti
Sito web	recursion.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	16/04/2021
Dipendenti	600